Figure 2.

Summary plot of symptom scores before and after dupilumab initiation. Symptoms are reported as “baseline score → on dupilumab score.” Scores were given based on the following: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. Shades of orange denote increase in score (worsening of symptoms), gray denotes no change in score, and shades of green denote decrease in score (improvement of symptoms) from baseline to on dupilumab. Black indicates that the symptom was absent before and after dupilumab initiation. Patients 1–8 are patients from the subanalysis for histologic effects of dupilumab. *Indicates patients who did not have histologic remission of EoD with dupilumab. EoE, eosinophilic esophagitis; EoD, eosinophilic duodenitis; EoG, eosinophilic gastritis.